0001193125-26-213322
SEC filingRevenue declined 10.2% to $47.2M due to product mix shift toward lower-priced minimally invasive bunion kits and reduced volumes, pressuring gross margins to 79.3% while operating losses widened amid cost dynamics, though cash generation strengthened from working capital.
Treace Medical Concepts reported Q1 FY2026 revenue of $47.2 million, down 10.2% from $52.6 million in the prior year quarter. This decline was primarily driven by a mix shift from higher-priced flagship Lapiplasty bunion procedure kits to lower-priced minimally invasive bunion procedure kits, coupled with lower overall volume of bunion procedure kits sold. These dynamics reflect changing customer preferences and market conditions affecting procedure adoption.
Operating income deteriorated to a -$17.2 million loss from -$15.6 million, a 10.2% worsening, as the revenue contraction outpaced the relative gross profit decline, resulting in an operating margin of -36.4%. Net income followed suit, reaching -$18.0 million versus -$15.9 million prior year, with diluted EPS at -$0.28 compared to -$0.25. These results highlight execution challenges in a competitive orthopedic foot and ankle market.
Cash flow provided a bright spot, with net cash from operating activities climbing to $7.2 million from $4.2 million, driven by favorable working capital timing including collections on prior period receivables and non-cash share-based compensation. After $3.1 million in capital expenditures—down from $3.5 million and primarily for new product surgical instruments—free cash flow totaled $4.2 million. The company funds operations through cash, marketable securities, and revenues to cover manufacturing costs, capex, and operating expenses.